<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="10" offset="1" totalResults="6530"><SearchResults><Trial Id="254264"><Indications><Indication>Asthma</Indication></Indications><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-06-02T00:00:00Z</DateChangeLast><DateEnd>2016-09-30T00:00:00Z</DateEnd><DateStart>2015-12-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02690831</Identifier><Identifier>UNIVERSIDAD AUTONOMA DE MADRID</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Inspiratory muscle training (IMT) alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Inspiratory muscle training (IMT) alone</Intervention><Intervention>Manual therapy and motor control exercise alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to assess if an intervention of manual therapy and motor control exercises combined with an inspiratory muscle training program was more effective than an inspiratory muscle training program alone in increasing the maximum inspiratory pressure in patients with asthma. In addition, the study pretends to evaluate the changes caused by the intervention regarding possible postural changes and thoracic diameter.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR)</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Asthma - Spirometry Unspecified</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effects of Manual Therapy and Respiratory Muscle Training on the Maximal Inspiratory Pressure in Patients With Asthma</TitleDisplay><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Maximal inspiratory mouth pressure </BiomarkerName><BiomarkerName> Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="345639"><Indications><Indication>End stage renal disease</Indication><Indication>Kidney dialysis</Indication></Indications><CompaniesCollaborator><Company>Fundacion Renal Inigo Alvarez De Toledo</Company><Company>Universidad Europea De Madrid</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universidad Politecnica de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2015-10-30T00:00:00Z</DateEnd><DateStart>2014-07-22T00:00:00Z</DateStart><Identifiers><Identifier>MARGARITA PÉREZ RUIZ</Identifier><Identifier>MGGROSS</Identifier><Identifier>NCT03579537</Identifier><Identifier>UNIVERSIDAD POLITÉCNICA MADRID</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Intradyalisis alone</Intervention><Intervention>exercise programe alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of the trial was to study the effects of exercise on physical fitness among hemodialysis patients with chronic kidney disease. Regular physical exercise was adapted to the situation of the patient with hemodialysis to help improve the quality of life of the patient.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Anthropometric Assessments</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Anxiety by Protocol Specified Scales - Assessment by Spielberger State-Trait Anxiety Inventory (STAI)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Depression Severity by Specific Criteria - Assessment by Beck Depression Inventory (BDI)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Hormone Levels - Assessment of Parathyroid hormone (PTH)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Electrolytes - Assessment of calcium</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Electrolytes - Assessment of plasma potassium</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Electrolytes - Assessment of sodium</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of iron status</EndpointIndex><EndpointIndex>End stage renal disease - Functional Assessment</EndpointIndex><EndpointIndex>End stage renal disease - Hematological Assessments - Assessment of hematocrit</EndpointIndex><EndpointIndex>End stage renal disease - Hematological Assessments - Assessment of hemoglobin levels</EndpointIndex><EndpointIndex>End stage renal disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by SF-36/SF-12</EndpointIndex><EndpointIndex>End stage renal disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effects of Exercise on Physical Fitness Among Hemodialysis Patients With Chronic Kidney Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Albumin </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Body fat percentage </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Chlorides </BiomarkerName><BiomarkerName> Fat mass </BiomarkerName><BiomarkerName> Ferritin </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Iron </BiomarkerName><BiomarkerName> Klotho </BiomarkerName><BiomarkerName> Mean corpuscular volume </BiomarkerName><BiomarkerName> Parathyroid hormone </BiomarkerName><BiomarkerName> Phosphorus </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Six-minute walk distance </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Total iron binding capacity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-07-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="380601"><Indications><Indication>Streptococcus pneumoniae infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Prophylactic vaccine</Action><Action>Subunit vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Protein conjugated</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-05-15T00:00:00Z</DateChangeLast><DateEnd>2016-04-30T00:00:00Z</DateEnd><DateStart>2007-05-01T00:00:00Z</DateStart><Identifiers><Identifier>HERACLES</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Prevnar 13 alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The aim of the study was to describe the population impact of the 13-valent pneumococcal conjugate vaccine ( PCV-13 ) on invasive pneumococcal disease (IPD) in children &amp;lt; 15 years of age in the Community of &lt;b&gt;Madrid&lt;/b&gt;, Spain [ 2151809 ].</Teaser><TrialCategories><Category>Biological</Category><Category>Vaccine</Category></TrialCategories><TitleDisplay>HERACLES: An observational, clinical surveillance study to determine the Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years in Madrid, Spain</TitleDisplay><PrimaryCompletionDate/><TrialDuration>108 Months</TrialDuration><NumberOfSites>0</NumberOfSites></Trial><Trial Id="341503"><Indications><Indication>Cognitive disorder</Indication></Indications><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-05-13T00:00:00Z</DateChangeLast><DateEnd>2023-09-30T00:00:00Z</DateEnd><DateStart>2016-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT03541135</Identifier><Identifier>SENIORS-ENRICA II</Identifier><Identifier>Sen-ENRICAII</Identifier></Identifiers><PatientCountEnrollment>2800</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Community-living subjects in the region of &lt;b&gt;Madrid&lt;/b&gt;, Spain, aged &amp;gt;/= 65 years will be included and observed in this study.... Non-institutionalized residents in the region of &lt;b&gt;Madrid&lt;/b&gt;, Spain Age &amp;gt;/= 65 years</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Physical Examination - Muscle strength/activity</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Neurological Assessments</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Physical Performance Battery Score (SPPB)</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Functional Disability/Physical Function - Assessment of daily activity/Work disability</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Mortality/Death Rates - Assessment of mortality</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Neuropsychological Function - Assessment of memory and learning</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of motor function</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Sen-ENRICAII: Study on Cardiovascular Health, Nutrition and Physical Functioning in Older Adults in Spain</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with specific disease</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with Cognitive disorder</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial stiffness </BiomarkerName><BiomarkerName> Augmentation index </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Gait </BiomarkerName><BiomarkerName> Muscle strength </BiomarkerName><BiomarkerName> Pulse wave velocity </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>92 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Fernando Rodríguez-Artalejo, MD, PhD</Name><Name>Jose R Banegas, MD, PhD</Name></ContactNames></Trial><Trial Id="313748"><Indications><Indication>Female infertility</Indication></Indications><ActionsPrimaryInterventionsControl><Action>GNRH receptor agonist</Action><Action>GNRH receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>GNRH receptor agonist</Action><Action>GNRH receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Proceptive</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Proceptive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Injectable formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2017-12-01T00:00:00Z</DateStart><Identifiers><Identifier>1702-MAD-014-MC</Identifier><Identifier>NCT03291821</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional ovarian stimulation alone</Intervention><Intervention>embryo freezing alone</Intervention><Intervention>embryo thawing alone</Intervention><Intervention>embryo transfer alone</Intervention><Intervention>intracytoplasmic sperm injection alone</Intervention><Intervention>ovarian puncture alone</Intervention><Intervention>trophectoderm biopsy alone</Intervention><Intervention>Variable regimens including Meriofert , cetrorelix , ganirelix acetate , human menopausal gonadotrophin , triptorelin pamoate</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>double ovarian stimulation (DuoStim) alone</Intervention><Intervention>embryo freezing alone</Intervention><Intervention>embryo thawing alone</Intervention><Intervention>embryo transfer alone</Intervention><Intervention>intracytoplasmic sperm injection alone</Intervention><Intervention>ovarian puncture alone</Intervention><Intervention>trophectoderm biopsy alone</Intervention><Intervention>Variable regimens including Meriofert , cetrorelix , ganirelix acetate , human menopausal gonadotrophin , triptorelin pamoate</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>136</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Signed informed consent Age 35 to 42 years Patients from the IVI &lt;b&gt;madrid&lt;/b&gt; undergoing controlled ovarian hyperstimulation cycle including PGT analysis for infertility treatment BMI 18 to 30 kg/m2 Suspicion of suboptimal or poor response: AMH&amp;lt; 1.5 ng/ml AFC&amp;lt; 8 FSH&gt; 10 Poor response in a previous cycle (defined as&amp;lt</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Infertility - Assessment of Embryo</EndpointIndex><EndpointIndex>Infertility - Assessment of Embryo - Assessment of embryo implantation rate</EndpointIndex><EndpointIndex>Infertility - Assessment of Embryo - Assessment of number of embryos transferred</EndpointIndex><EndpointIndex>Infertility - Assessment of Oocytes - Assessment of number of oocytes fertilised</EndpointIndex><EndpointIndex>Infertility - Assessment of Ovarian Function - Assessment of ovarian stimulation</EndpointIndex><EndpointIndex>Infertility - Assessment of Pregnancy - Assessment of pregnancy loss</EndpointIndex><EndpointIndex>Infertility - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Infertility - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Infertility - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART)</PatientSegment><PatientSegment>Infertility - Subjects with Histroy of Infertility - Women with infertility</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2018-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Fernando Bronet</Name><Name>Gustavo N Cecchino, M.D.</Name><Name>Javier MS Romero, M.D.</Name><Name>Juan A Garcia Velasco, M.D., Ph.D.</Name><Name>Maria Cerrillo, M.D., Ph.D.</Name><Name>Maria Cruz</Name><Name>Mónica T Paredes</Name></ContactNames></Trial><Trial Id="348161"><Indications><Indication>HIV infection</Indication><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatitis C virus NS3 protease inhibitor</Action><Action>Hepatitis C virus NS5B polymerase inhibitor</Action><Action>Hepatitis C virus protein NS5A inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Hepatitis C virus replication inhibitor</Action><Action>RNA synthesis inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital General Universitario Gregorio Marañon</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-09-05T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>paritaprevir + ritonavir + ombitasvir + dasabuvir (oral, HCV infection) AbbVie alone</Intervention><Intervention>sofosbuvir + ledipasvir (fixed-combination/oral, HCV/HBV), Gilead alone</Intervention><Intervention>Variable regimens including Daklinza , ribavirin , simeprevir , sofosbuvir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2369</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser> The aim of this observational study was to evaluate treatment outcomes of interferon-free direct-acting antiviral agent-based therapy in patients with human immunodeficiency virus/hepatitis C virus (HCV)-coinfection enrolled in a prospective &lt;b&gt;Madrid&lt;/b&gt; coinfection registry [ 2058860 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><TitleDisplay>A real-world, Madrid coinfection registry finding study on the effect of all-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in patients with human immunodeficiency virus/HCV-coinfection</TitleDisplay><BiomarkerNames><BiomarkerName>Hepatitis C virus RNA </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="374084"><Indications><Indication>Myalgia</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-22T00:00:00Z</DateChangeLast><DateEnd>2019-06-20T00:00:00Z</DateEnd><DateStart>2019-03-12T00:00:00Z</DateStart><Identifiers><Identifier>NCT03872063</Identifier><Identifier>RADO</Identifier></Identifiers><InterventionsControlDisplay><Intervention>eccentric exercises alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>eccentric exercises alone</Intervention><Intervention>myofascial induction technique alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Volleyball players Both gender Age range of 18 to 35 years Compete in a federated team in the Community of &lt;b&gt;Madrid&lt;/b&gt;</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment by Global Assessment Scales - Visual analogue scales (VAS) for local and general pain/overall disease activity</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Clinical Assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Myofascial Induction and Eccentric Exercises in Volleyball Players</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with specific disease</PatientSegment><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Shoulder motion</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Rubén Cuesta-Barriuso, PhD</Name></ContactNames></Trial><Trial Id="204979"><Indications><Indication>Cystic fibrosis</Indication></Indications><CompaniesCollaborator><Company>Hospital Infantil Universitario Nino Jesus</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-15T00:00:00Z</DateChangeLast><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>CFTRAINING</Identifier><Identifier>KID'STRAININGCF</Identifier><Identifier>NCT01706445</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Aerobic training alone</Intervention><Intervention>Inspiratory muscle training alone</Intervention><Intervention>Strength training alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Boy/girl aged 6 to 17 years Living in the &lt;b&gt;Madrid&lt;/b&gt; area</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Exercise Capacity/Tolerance - Assessment of muscle strength</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by CF_questionnaire_revised(CFQ_R)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Combined Inspiratory Muscle and 'Whole Muscle' Training in Children With Cystic Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Pediatric Cystic Fibrosis Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Maximal inspiratory mouth pressure </BiomarkerName><BiomarkerName> Maximal oxygen uptake</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-07-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites></Trial><Trial Id="377117"><Indications><Indication>Factor VIII deficiency</Indication><Indication>Musculoskeletal disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor VIII agonist</Action><Action>Factor VIII modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Blood clotting modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Protein fusion</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-19T00:00:00Z</DateChangeLast><DateEnd>2020-12-15T00:00:00Z</DateEnd><DateStart>2019-09-02T00:00:00Z</DateStart><Identifiers><Identifier>LONGHEST</Identifier><Identifier>NCT03914209</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>efmoroctocog alfa alone</Intervention><Intervention>factor VIII therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This is a multicenter, observational clinical study. A total of 40 patients with hemophilia A will be included in this study. Patients will be recruited from five centers located in various regions of Spain (Community of &lt;b&gt;Madrid&lt;/b&gt;, Galicia, Community of Valenciana, Málaga and Vizcaya). The dependent variables will be: bleeding frequency (self-report of bleeding), changes in the dosage of factor VIII with EHL products ( rFVIIIFc ), pain (measured with the visual analog scale and a pressure Algometer)</Teaser><TrialCategories><Category>Biological</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Clinical Symptoms - Assessment of bleeding episodes</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Co-morbidity - Assessment of hematologic diseases/disorders</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Exercise Capacity/Tolerance - Assessment of muscle strength</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hemophilia - Assessment of blood loss</EndpointIndex><EndpointIndex>Hemophilia - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Hemophilia - Assessment of pain</EndpointIndex><EndpointIndex>Hemophilia - Clinical Assessments - Assessment of neuropsychiatric function</EndpointIndex><EndpointIndex>Hemophilia - Patient Reported Outcomes/Quality of Life Assessments - Hemophilia Joint Health Score (HJHS)</EndpointIndex><EndpointIndex>Hemophilia - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Others - Healthy Subjects</PatientSegment><PatientSegment>Hemophilia - Subjects with Hemophilia A</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Muscle strength </BiomarkerName><BiomarkerName> Six-minute walk distance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-11-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Rubén Cuesta-Barriuso, PhD</Name></ContactNames></Trial><Trial Id="204862"><Indications><Indication>Aneuploidy</Indication></Indications><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateEnd>2012-12-31T00:00:00Z</DateEnd><DateStart>2010-07-31T00:00:00Z</DateStart><Identifiers><Identifier>MAD-FB-04-2010-01</Identifier><Identifier>NCT01164943</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>human FSH alone</Intervention><Intervention>recombinant follicle stimulating hormone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>The aim of this study was to observe if there was a difference in aneuploidy rate and morphological oocyte parameters between different stimulation protocols.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Infertility - Assessment of Oocytes</EndpointIndex><EndpointIndex>Infertility - Assessment of Pregnancy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Aneuploidy Rate and Stimulation Protocol: recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Oocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>David Agudo</Name><Name>Eva Martinez</Name><Name>Fernando Bronet</Name></ContactNames></Trial></SearchResults></trialResultsOutput>